The FDA cleared a generic Infuvite Pediatric injection for children receiving parenteral nutrition, adding a new option for hospital supply.
The FDA has approved an abbreviated new drug application for a generic version of Infuvite Pediatric Injection, a multivitamin product used as part of intravenous nutrition support in children, according to an April 27, 2026, announcement from Apotex. The company said the product is eligible for 180-day competitive generic therapy exclusivity for the single-dose vial presentation, a designation intended to encourage market entry for drugs with limited generic competition.1
The approval is clinically relevant because pediatric parenteral multivitamin products are a routine component of parenteral nutrition in infants and children who cannot meet nutritional requirements enterally, including patients in neonatal and pediatric intensive care settings and those with intestinal failure. In a statement, Apotex said the authorization “expand[s] access to parenteral nutrition options for both adult and pediatric patients.”1
The newly approved product follows the April 13, 2026, approval of a generic Infuvite Adult Injection, according to the release.1 Although the release did not provide prescribing details, Infuvite Pediatric is the reference multivitamin formulation intended for pediatric patients receiving intravenous nutrition support. FDA approval through the abbreviated new drug application pathway indicates that the agency found the generic to be comparable to the reference listed drug in key regulatory standards, including pharmaceutical equivalence and bioequivalence requirements, where applicable.2
Parenteral multivitamin products occupy a small but important niche in hospital and home nutrition practice. In pediatric patients who depend on parenteral nutrition, omitting multivitamins can contribute to deficiencies affecting growth, wound healing, immune function, hematopoiesis, and neurologic development. ASPEN guidance has emphasized that pediatric parenteral nutrition formulations should include age-appropriate vitamin supplementation, while also recognizing that product shortages have periodically complicated practice in the US.3
The approval may therefore matter less as a novel therapeutic advance than as a development in supply and access. Injectable nutrition support products have been vulnerable to manufacturing disruptions, and additional approved suppliers can help reduce supply chain fragility. Still, clinicians will need to review labeling, vial presentation, excipients, and compatibility information once the product becomes commercially available, particularly in neonatal and small-volume dosing workflows.
Infuvite products contain combinations of water-soluble and fat-soluble vitamins formulated for intravenous administration. In practice, these agents are used adjunctively within broader parenteral nutrition regimens rather than as stand-alone therapies. Their role is well established, but product selection is shaped by patient age, dosing requirements, admixture practices, and institutional formulary considerations.3
The FDA’s competitive generic therapy pathway was created for drugs that lack sufficient generic competition and can confer 180 days of exclusivity to the first approved applicant that meets marketing requirements.2 For clinicians, that regulatory detail is less important than whether the product reaches hospitals and outpatient infusion settings promptly and whether it improves the reliability of access.
The news release did not include launch timing, pricing, pediatric age-stratification, or comparative data beyond the approval.1 It also did not report safety findings from the regulatory review. As with the reference product, safety considerations for parenteral multivitamins generally include hypersensitivity reactions and the potential for dosing errors, especially in vulnerable pediatric populations.3,4 Postmarketing uptake will likely depend on distribution, contracting, and institutional adoption rather than FDA approval alone.
For pediatricians, neonatologists, gastroenterologists, and nutrition support teams, the key implication is that another FDA-approved option may soon be available in a category where redundancy can be clinically meaningful. Whether the approval translates into better bedside access will become clearer after commercialization.
